Besunyen Holdings Company Limited provided unaudited consolidated earnings guidance for the year 2016. The company, expected that the Group may record a net loss attributable to the shareholders of the company of approximately RMB 50 million to RMB 70 million for the year 2016. This is mainly attributable to: (i) the manufacture of the Group's slimming tea products has been suspended for more than half a year due to delay in obtaining the Approval, the slimming tea products in sale are out of stock in some sales regions, thereby having affected the sale of the slimming tea products; (ii) the relevant selling and marketing expenses of the slimming medicine Orlistat under the brand of 'LARLLY'' for the year 2016 are expected to increase significantly as compared to that for the year 2015.